Research Service, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417, USA.
Bioorg Med Chem Lett. 2010 Jan 1;20(1):403-5. doi: 10.1016/j.bmcl.2009.10.046. Epub 2009 Oct 15.
The transition from G1 to S phase in the cell cycle is highly regulated by Cdk4 and Cdk6, which in turn is inhibited by the tumor suppressor p16(INK4a). Replacement of lost p16(INK4a) activity in cancer cells via gene therapy has worked in vivo to decrease tumor progression; however, practical issues limit gene therapy applications at this time. Here, we report the discovery of compounds that inhibit Cdk4 and Cdk6 activity. The NMR structure of a peptide that exhibits p16(INK4a) activity was solved and combined with known functional data to generate a pharmacophore that was used to mine the NCI chemical database. The hits were filtered utilizing the program Qikprop. Four compounds were subsequently shown to inhibit Cdk4 and/or Cdk6 with IC(50) in the muM range. These compounds form lead compounds upon which further cell cycle inhibitors can be developed.
细胞周期从 G1 期向 S 期的转变受到 Cdk4 和 Cdk6 的高度调控,而 Cdk4 和 Cdk6 又受到肿瘤抑制因子 p16(INK4a)的抑制。通过基因治疗在体内替换癌细胞中丢失的 p16(INK4a)活性已被证明可降低肿瘤进展;然而,实际问题限制了目前基因治疗的应用。在这里,我们报告了发现抑制 Cdk4 和 Cdk6 活性的化合物。解决了表现出 p16(INK4a)活性的肽的 NMR 结构,并结合已知的功能数据生成了一个药效团,用于挖掘 NCI 化学数据库。利用程序 Qikprop 对命中物进行了过滤。随后有 4 种化合物被证明能以 μM 范围内的 IC50 抑制 Cdk4 和/或 Cdk6。这些化合物形成了进一步开发细胞周期抑制剂的先导化合物。